Cáncer de próstata metastásico: adelantar el 177Lu-PSMA-617 a la primera línea hormonal mejora el control (PSMAddition)

177Lu-PSMA-617 first-line metastatic prostate cancer therapy

·

🤖 Generated with AI assistance · Does not replace individualized medical advice.

PSMAddition: Early 177Lu-PSMA-617 Improves Control in Metastatic Prostate Cancer

The PSMAddition study demonstrates that adding 177Lu-PSMA-617 to first-line hormonal therapy improves disease control in metastatic prostate cancer, challenging the traditional sequence of treatment lines.

Why it matters

While 177Lu-PSMA-617 has established value in castration-resistant prostate cancer (mCRPC), clinicians have long questioned its efficacy when introduced earlier in the disease course. This analysis highlights that integrating this radioligand with initial hormonal treatment offers superior control compared to standard care alone.

Clinical takeaway

Consider early integration of 177Lu-PSMA-617 with hormonal therapy for eligible patients with metastatic prostate cancer to enhance disease control.

Read the full article: Cáncer de próstata metastásico: adelantar el 177Lu-PSMA-617 a la primera línea hormonal mejora el control (PSMAddition)

Originally published on ppj.es by Dr. Javier Pumares.

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Powered by